Progress and prospect of treatment for ocular Behçet disease

Authors:Bai Lin,  Yang Peizeng
DOI: 10.3760/cma.j.issn.2095-0160.2016.08.020
Published 2016-08-10
Cite as Chin J Exp Ophthalmol, 2016,34(8): 761-764.

Abstract

Ocular Behçet disease, which usually presents as panuveitis, with characteristic of vision impairment and relapse, is one of the most refractory uveitis entities.Usually, one or more conventional immunosuppressive agents, such as glucocorticoid, ciclosporin, chlorambucil, cyclophosphamide, etc, are needed in disease management.However, long-term use of immunosuppressive agents would result in severe adverse effects.New biologics, such as interferon, antitumor necrosis factor agents, interleukin or its receptor antagonists, provide new therapeutic approaches to the treatment for this disease.This paper reviewed the conventional therapies and biologics applied in ocular Behçet disease.

Key words:

Behçet disease, Uveitis; Treatment; Immunosuppressive agent; Biologics

Contributor Information

Bai Lin
Affiliated First Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Istitute, Chongqing 400016, China
Yang Peizeng
(Read 54 times, 1 visits today)
Updated: October 8, 2019 — 9:30 am